Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.
Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, Katayama Y, Ozawa Y, Matsuoka KI, Kawakita T, Mori Y, Ara T, Nakamae H, Kimura T, Kanda Y, Atsuta Y, Ogata M; Transplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy. Saburi M, et al. Among authors: kanda y. Ann Hematol. 2023 Sep;102(9):2507-2516. doi: 10.1007/s00277-023-05320-4. Epub 2023 Jun 20. Ann Hematol. 2023. PMID: 37338625
In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.
Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, Izutsu K, Hangaishi A, Tsujino S, Ogawa S, Motokura T, Chiba S, Hirai H. Kanda Y, et al. Transplantation. 2005 May 27;79(10):1351-7. doi: 10.1097/01.tp.0000158718.49286.14. Transplantation. 2005. PMID: 15912103 Clinical Trial.
Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, Watanabe T, Asai T, Izutsu K, Ogawa S, Motokura T, Chiba S, Kurokawa M. Oshima K, et al. Among authors: kanda y. Am J Hematol. 2006 Nov;81(11):875-9. doi: 10.1002/ajh.20694. Am J Hematol. 2006. PMID: 16862551 Free article.
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y. Saito AM, et al. Among authors: kanda y. Am J Hematol. 2007 Oct;82(10):873-80. doi: 10.1002/ajh.20977. Am J Hematol. 2007. PMID: 17570513 Free article. Clinical Trial.
Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases.
Miyakoshi S, Kusumi E, Matsumura T, Hori A, Murashige N, Hamaki T, Yuji K, Uchida N, Masuoka K, Wake A, Kanda Y, Kami M, Tanaka Y, Taniguchi S. Miyakoshi S, et al. Among authors: kanda y. Biol Blood Marrow Transplant. 2007 Jul;13(7):771-7. doi: 10.1016/j.bbmt.2007.02.012. Biol Blood Marrow Transplant. 2007. PMID: 17580255 Free article.
1,359 results